Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Open-Label Case Study to Assess a Brightening Skincare Regimen in Patients With Bothersome Skin Dark Spots

NCT07933380 is registered in ClinicalTrials.gov with Revision Skincare as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07933380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Open-Label Case Study to Assess a Brightening Skincare Regimen in Patients With Bothersome Skin Dark Spots
Lead sponsor
Revision Skincare
Phase
Not applicable
Overall status
Completed
Start date
February 10, 2026
Completion date
July 7, 2026
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pigmentation, post - inflammatory hyperpigmentation

Arms

As registered; 1 arm.

  • Brightening Serum and Brightening Pads ExperimentalCleanser, Moisturizer, and Sunscreen

    From baseline to week 12, subjects will apply a Brightening Serum (2x daily), and brightening pads 3 times per week in the evening only (Monday, Wednesday, Friday) or (Tuesday, Thursday, Saturday).

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Improvement of Clinical Efficacy Parameters at 2, 4, 8, and 12 weeks versus Baseline Weeks 2, 4, 8, and 12 compared to baseline

    A board-certified dermatologist will grade skin tone evenness, overall appearance, and PIH at baseline and at weeks 2, 4, 8, and 12. Skin tone evenness and overall appearance will be graded using the modified Griffiths 10-point scale (0 = Even healthy skin color; 9 = Uneven, discolored appearance), while PIH will be measured using a 4-point investigator global assessment scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). Higher scores indicate greater severity of the respective skin condition, where a decrease in score indicates an improvement.

  • Measurement of subject self assessment questionnaire Baseline, weeks 2, 4, 8, and 12

    Subjects will complete a self-assessment questionnaire which will consist of a series of questions related to subjects' evaluation of product efficacy and attributes. Subjects are asked to rate based on a scoring system of the following: from 5 (completely agree) to 1 (completely disagree). The best outcome is to Completely Agree with the statement / question being asked.

Lead sponsor's other trials

Revision Skincare, most recent start first.

Similar trials

Same condition (Hyperpigmentation) and phase, most recent start first.